{"id":"gammaplex-5","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Chills"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Myalgia"},{"rate":null,"effect":"Infusion reactions"},{"rate":null,"effect":"Thrombosis (rare)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Gammaplex contains immunoglobulin G (IgG) antibodies derived from pooled human plasma, which are administered intravenously to patients with primary or secondary immunodeficiencies. The antibodies provide immediate passive immunity, helping to prevent or treat infections and modulate immune responses in conditions where antibody production is deficient or dysfunctional.","oneSentence":"Gammaplex is an intravenous immunoglobulin (IVIG) preparation that provides passive immunity by delivering pooled human antibodies to boost immune function.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:31:07.667Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Primary immunodeficiency disorders"},{"name":"Secondary immunodeficiency (e.g., chronic lymphocytic leukemia, HIV)"},{"name":"Idiopathic thrombocytopenic purpura (ITP)"},{"name":"Chronic inflammatory demyelinating polyneuropathy (CIDP)"},{"name":"Multifocal motor neuropathy"}]},"trialDetails":[{"nctId":"NCT06859424","phase":"PHASE2","title":"A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation","status":"RECRUITING","sponsor":"Center for International Blood and Marrow Transplant Research","startDate":"2025-07-25","conditions":"AML (Acute Myelogenous Leukemia), Acute Lymphoid Leukemia (ALL), Acute Leukemia (Category)","enrollment":358},{"nctId":"NCT07410039","phase":"PHASE4","title":"Therapy in the Acute Phase of NMOSD: A Multicenter Prospective Real-World Study","status":"RECRUITING","sponsor":"Chinese PLA General Hospital","startDate":"2026-02-01","conditions":"Neuromyelitis Optica Spectrum Disorder Attack","enrollment":200},{"nctId":"NCT05701189","phase":"PHASE2","title":"Evaluating Efgartigimod in Patients With Guillain-Barré Syndrome","status":"WITHDRAWN","sponsor":"Chafic Karam","startDate":"2024-09-10","conditions":"Guillain-Barre Syndrome","enrollment":""},{"nctId":"NCT04965597","phase":"PHASE2","title":"Treosulfan-Based Conditioning Regimen Before a Blood or Bone Marrow Transplant for the Treatment of Bone Marrow Failure Diseases (BMT CTN 1904)","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2022-04-19","conditions":"Bone Marrow Failure Syndrome, Congenital Amegakaryocytic Thrombocytopenia, Diamond-Blackfan Anemia","enrollment":40},{"nctId":"NCT05350774","phase":"PHASE2","title":"Immunotherapy for Neurological Post-Acute Sequelae of SARS-CoV-2","status":"ENROLLING_BY_INVITATION","sponsor":"National Institute of Neurological Disorders and Stroke (NINDS)","startDate":"2023-07-10","conditions":"Systemic Inflammation, Neuroinflammation, Microvascular Thrombosis","enrollment":45},{"nctId":"NCT03849651","phase":"PHASE2","title":"TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2019-01-31","conditions":"Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS)","enrollment":69},{"nctId":"NCT05832034","phase":"PHASE2, PHASE3","title":"Add-on Intravenous Immunoglobulins in Early Myositis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2021-09-13","conditions":"Inflammatory Myopathy, Idiopathic, Dermatomyositis, Antisynthetase Syndrome","enrollment":44},{"nctId":"NCT04438382","phase":"PHASE2","title":"Infliximab and Intravenous Immunoglobulin Therapy in Treating Patients With Steroid-Refractory Pneumonitis","status":"TERMINATED","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2021-01-07","conditions":"Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Steroid-Refractory Pneumonitis","enrollment":1},{"nctId":"NCT05662228","phase":"PHASE2","title":"Therapies for Down Syndrome Regression Disorder","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Colorado, Denver","startDate":"2023-06-29","conditions":"Down Syndrome, Regression","enrollment":66},{"nctId":"NCT03286556","phase":"PHASE2","title":"Autoantibody Reduction for Acute Exacerbations of Idiopathic Pulmonary Fibrosis","status":"COMPLETED","sponsor":"University of Alabama at Birmingham","startDate":"2018-09-04","conditions":"Idiopathic Pulmonary Fibrosis, Acute Fatal Form","enrollment":82},{"nctId":"NCT04224558","phase":"PHASE1, PHASE2","title":"Stem Cell Transplantation in Crohn's Disease","status":"RECRUITING","sponsor":"Cedars-Sinai Medical Center","startDate":"2019-11-15","conditions":"Crohn Disease","enrollment":15},{"nctId":"NCT07264517","phase":"PHASE2","title":"Evaluating the Safety, Tolerability, and Efficacy of GRF312 5% in Participants With Dry Eye Disease (DED).","status":"RECRUITING","sponsor":"Instituto Grifols, S.A.","startDate":"2025-11-03","conditions":"Dry Eye Disease","enrollment":100},{"nctId":"NCT02201576","phase":"PHASE2","title":"Bortezomib in Rejection of Kidney Transplants","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2015-02-11","conditions":"Chronic Antibody-mediated Transplant Rejection","enrollment":60},{"nctId":"NCT05952804","phase":"PHASE2","title":"IVIG for Infection Prevention After CAR-T-Cell Therapy","status":"RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2024-06-10","conditions":"Hematologic Malignancies","enrollment":150},{"nctId":"NCT06954441","phase":"PHASE3","title":"V-IMMUNE: A Novel Immunoglobulin Therapy for Immunodeficiency","status":"RECRUITING","sponsor":"On Pharma Importadora, Exportadora e Distribuidora de Medicamentos LTDA.","startDate":"2025-08-15","conditions":"Immunodeficiencies, Primary Immunodeficiencies (PID), Agammaglobulinemia","enrollment":50},{"nctId":"NCT03961555","phase":"PHASE2","title":"Comparison of SYN023 to Human Rabies Immune Globulin in Post Exposure Prophylaxis of Rabies","status":"COMPLETED","sponsor":"Synermore Biologics Co., Ltd.","startDate":"2019-09-03","conditions":"Rabies","enrollment":448},{"nctId":"NCT03292861","phase":"PHASE2","title":"The Effect and Safety Profile of Thymoglobulin® in Primary Cardiac Transplant Recipients","status":"ENROLLING_BY_INVITATION","sponsor":"Cedars-Sinai Medical Center","startDate":"2018-09-13","conditions":"Heart Transplantation","enrollment":60},{"nctId":"NCT01596335","phase":"PHASE3","title":"Clinical Study of TA-650 in Patients With Refractory Kawasaki Disease","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2012-05","conditions":"Kawasaki Disease Refractory to Initial Therapy With Intravenous Immunoglobulin","enrollment":31},{"nctId":"NCT04078568","phase":"PHASE3","title":"Efficacy of Immunoglobulin Plus Prednisolone in Reducing Coronary Artery Lesion in Patients With Kawasaki Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Hospital of Fudan University","startDate":"2020-01-15","conditions":"Kawasaki Disease","enrollment":3208},{"nctId":"NCT05457556","phase":"PHASE3","title":"Mismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for Children, Adolescents, and Young Adults With Acute Leukemia or Myelodysplastic Syndrome","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2023-03-15","conditions":"Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Mixed Phenotype Acute Leukemia","enrollment":435},{"nctId":"NCT06958796","phase":"PHASE4","title":"Strategic Help With Immunoglobulin to Enhance Protect Against Late Disease (CMV)","status":"RECRUITING","sponsor":"Camille N. Kotton, MD","startDate":"2025-11-27","conditions":"Cytomegalovirus, Organ Transplant, Kidney Transplant; Complications","enrollment":80},{"nctId":"NCT04083183","phase":"PHASE1, PHASE2","title":"Total Body Irradiation and Astatine-211-Labeled BC8-B10 Monoclonal Antibody for the Treatment of Nonmalignant Diseases","status":"RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2020-06-16","conditions":"Non-Malignant Neoplasm","enrollment":40},{"nctId":"NCT07233213","phase":"PHASE3","title":"An Open-label Study of Intravenous Immunoglobulin (5%) for the Treatment of Primary Immune Thrombocytopenia","status":"RECRUITING","sponsor":"Grand Shuyang Life Sciences (Chengdu) Co., Ltd.","startDate":"2025-11-24","conditions":"Primary Immune Thrombocytopenia (ITP)","enrollment":36},{"nctId":"NCT05645107","phase":"PHASE3","title":"A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma","status":"RECRUITING","sponsor":"Grifols Therapeutics LLC","startDate":"2022-12-26","conditions":"Hypogammaglobulinemia, Bacterial Infections, B-cell Chronic Lymphocytic Leukemia","enrollment":386},{"nctId":"NCT07076446","phase":"PHASE4","title":"An Open-label, Multicenter Study to Assess the Pharmacokinetics (PK), Safety, and Tolerability of Subcutaneous IgPro20 in Immunoglobulin (IG) Treatment-naïve Participants With Primary Immunodeficiency (PID)","status":"RECRUITING","sponsor":"CSL Behring","startDate":"2025-07-15","conditions":"Primary Immunodeficiency","enrollment":8},{"nctId":"NCT05494593","phase":"PHASE4","title":"A Study of ELAPRASE in Treatment-naïve Participants With Hunter Syndrome (Mucopolysaccharidosis [MPS] II)","status":"WITHDRAWN","sponsor":"Takeda","startDate":"2023-02-28","conditions":"Mucopolysaccharidosis (MPS), Hunter Syndrome","enrollment":""},{"nctId":"NCT02176863","phase":"PHASE2, PHASE3","title":"Study of the Efficacy and Safety of Immune Globulin Intravenous (Human) Flebogamma® 5% Dual Inactivation and Filtration (DIF) in Participants With Post-polio Syndrome","status":"TERMINATED","sponsor":"Instituto Grifols, S.A.","startDate":"2014-09-23","conditions":"Post-polio Syndrome","enrollment":191},{"nctId":"NCT04701034","phase":"PHASE2","title":"Intravenous Immunoglobulin and Prednisolone for RPL After ART.","status":"COMPLETED","sponsor":"Aalborg University Hospital","startDate":"2021-01-28","conditions":"Habitual Abortion, Recurrent Pregnancy Loss, Fertility Disorders","enrollment":80},{"nctId":"NCT07231523","phase":"PHASE3","title":"EFG vs IVIG in TAMG","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2025-12-01","conditions":"Efgartigimod, Intravenous Immunoglobulin, Myasthenia Gravis Associated With Thymoma","enrollment":64},{"nctId":"NCT06935266","phase":"PHASE1","title":"A Study of TAK-881 With and Without Ramp-Up Dosing in Healthy Adults","status":"COMPLETED","sponsor":"Takeda","startDate":"2025-04-22","conditions":"Healthy Volunteers","enrollment":64},{"nctId":"NCT07193953","phase":"PHASE1","title":"Intravenous Immunoglobulin (IVIG) and Blood-Brain Barrier Disruption in Amyotrophic Lateral Sclerosis (ALS)","status":"RECRUITING","sponsor":"Sunnybrook Health Sciences Centre","startDate":"2025-04-15","conditions":"Amyotrophic Lateral Sclerosis, ALS","enrollment":6},{"nctId":"NCT02219165","phase":"PHASE2","title":"Efficacy of IntraVenous ImmunoGlobulins in Toxic Shock Syndromes: a Paediatric Pilot Study","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2015-01-08","conditions":"Toxic Shock Syndrome","enrollment":30},{"nctId":"NCT03939637","phase":"PHASE3","title":"Eltrombopag vs Standard Front Line Management for Newly Diagnosed Immune Thrombocytopenia (ITP) in Children","status":"COMPLETED","sponsor":"Baylor College of Medicine","startDate":"2019-05-02","conditions":"Immune Thrombocytopenia","enrollment":122},{"nctId":"NCT07068126","phase":"NA","title":"Management of Children With Persistent ITP, A Novel Approach","status":"RECRUITING","sponsor":"Assiut University","startDate":"2025-01-01","conditions":"Persistent Immune Thrombocytopenia","enrollment":20},{"nctId":"NCT04400994","phase":"PHASE2","title":"IVIG With Rituximab vs Rituximab as First Line Treatment of Pemphigus","status":"ACTIVE_NOT_RECRUITING","sponsor":"The University of Hong Kong","startDate":"2020-06-20","conditions":"Pemphigus","enrollment":20},{"nctId":"NCT04530487","phase":"PHASE2","title":"Donor Stem Cell Transplant After Chemotherapy for the Treatment of Recurrent or Refractory High-Risk Solid Tumors in Pediatric and Adolescent-Young Adults","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2020-08-19","conditions":"Desmoplastic Small Round Cell Tumor, Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Desmoplastic Small Round Cell Tumor","enrollment":1},{"nctId":"NCT03542279","phase":"NA","title":"CPI Combination Therapy for Autoimmune Encephalitis","status":"COMPLETED","sponsor":"Xuanwu Hospital, Beijing","startDate":"2020-11-25","conditions":"Autoimmune Encephalitis","enrollment":70},{"nctId":"NCT03194815","phase":"PHASE2","title":"IVIG and Rituximab in Antibody-associated Psychosis - SINAPPS2","status":"RECRUITING","sponsor":"University of Cambridge","startDate":"2017-11-01","conditions":"Psychosis, Autoimmune Encephalitis","enrollment":70},{"nctId":"NCT05114941","phase":"NA","title":"Comparison of the Efficacy and Safety of Immunoadsorption and Intravenous Immunoglobulin for Guillain-Barre Syndrome","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital of Zhengzhou University","startDate":"2026-01-01","conditions":"Guillain-Barre Syndrome","enrollment":204},{"nctId":"NCT06373211","phase":"PHASE2","title":"Early Immunotherapy with Intravenous Immunoglobulin, Cyclophosphamide and Methylprednisolone in Patients with Anti-Hu-associated Paraneoplastic Sensory Neuronopathy","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2025-01-10","conditions":"Paraneoplastic Sensory Neuronopathy","enrollment":21},{"nctId":"NCT06686927","phase":"PHASE2","title":"Study on Glucocorticoid Combined With Gamma Globulin and Ropristine N01 in Treatment of Initial Severe ITP","status":"RECRUITING","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2024-11-20","conditions":"Primary Immune Thrombocytopenia","enrollment":36},{"nctId":"NCT04881682","phase":"PHASE2","title":"Immunoadsorption Versus Immunoglobulins for Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)","status":"RECRUITING","sponsor":"University of Ulm","startDate":"2023-05-01","conditions":"CIDP","enrollment":20},{"nctId":"NCT06696807","phase":"","title":"Immunomodulatory Therapy & VSA","status":"COMPLETED","sponsor":"Dao Wen Wang","startDate":"2018-10-01","conditions":"Vasospastic Angina","enrollment":71},{"nctId":"NCT04521946","phase":"PHASE1","title":"Chemotherapy and Donor Stem Transplant for the Treatment of Patients With High Grade Brain Cancer","status":"WITHDRAWN","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-01-14","conditions":"Anaplastic Ependymoma, Atypical Teratoid/Rhabdoid Tumor, Central Nervous System Germ Cell Tumor","enrollment":""},{"nctId":"NCT04776850","phase":"EARLY_PHASE1","title":"Pre-transplant Immunosuppression and Donor Stem Cell Transplant for the Treatment of Severe Hemoglobinopathies","status":"WITHDRAWN","sponsor":"M.D. Anderson Cancer Center","startDate":"2020-12-29","conditions":"Beta Thalassemia Major, Sickle Beta 0 Thalassemia, Sickle Beta Plus Thalassemia","enrollment":""},{"nctId":"NCT06577909","phase":"PHASE2","title":"Prednisone Plus IVIg vs. Prednisone for ITP During Pregnancy","status":"RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2023-10-19","conditions":"Immune Thrombocytopenia","enrollment":100},{"nctId":"NCT04302805","phase":"PHASE3","title":"rATG Versus rATG Combined With Intravenous Immunoglobulin (IVIG) Induction Immunosuppression in HLA Incompatible Transplantation (INHIBIT)","status":"COMPLETED","sponsor":"Institute for Clinical and Experimental Medicine","startDate":"2020-07-27","conditions":"Kidney Transplantation","enrollment":17},{"nctId":"NCT06534450","phase":"PHASE3","title":"The Effects Of Therapeutic Plasma Exchange (TPE) On Age Related Biomarkers And Epigenetics","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dobri Kiprov","startDate":"2022-09-12","conditions":"Aging","enrollment":40},{"nctId":"NCT06068608","phase":"PHASE1","title":"A Trial to Evaluate the Safety, Pharmacokinetics and Pharmacodynamic Profile of TNM005 in Healthy Adult Subjectsy","status":"UNKNOWN","sponsor":"Zhuhai Trinomab Pharmaceutical Co., Ltd.","startDate":"2023-09-12","conditions":"Varicella","enrollment":48},{"nctId":"NCT02915263","phase":"PHASE2","title":"The Efficacy Of Intravenous Immunoglobulin Therapy In Treatment Induced Neuropathy Of Diabetes","status":"TERMINATED","sponsor":"Beth Israel Deaconess Medical Center","startDate":"2017-09-11","conditions":"Diabetes Complications, Diabetes Mellitus, Diabetic Neuropathies","enrollment":13},{"nctId":"NCT04137224","phase":"PHASE2","title":"Safety and Pharmacokinetics of IgPro20 and IgPro10 in Adults With Systemic Sclerosis (SSc)","status":"COMPLETED","sponsor":"CSL Behring","startDate":"2019-09-19","conditions":"Diffuse Cutaneous Systemic Sclerosis","enrollment":27},{"nctId":"NCT06223984","phase":"PHASE4","title":"Combined Use of Immunoglobulin and Pulse Steroid Therapies in Severe Covid-19 Patients","status":"COMPLETED","sponsor":"Konya City Hospital","startDate":"2020-03-30","conditions":"Pulse Steroid and Immunoglobulins Drugs in Covid 19 Patients","enrollment":178},{"nctId":"NCT04381936","phase":"PHASE3","title":"Randomised Evaluation of COVID-19 Therapy","status":"RECRUITING","sponsor":"University of Oxford","startDate":"2020-03-19","conditions":"Severe Acute Respiratory Syndrome","enrollment":70000},{"nctId":"NCT04578535","phase":"PHASE1","title":"A Study to Assess the Tolerability, Safety, and Pharmacokinetics of Subcutaneous Immune Globulin Infusion 10% (Human) With Recombinant Human Hyaluronidase (HYQVIA/HyQvia) With Ramp-up and No Ramp-up Dosing in Healthy Adult Participants","status":"COMPLETED","sponsor":"Baxalta now part of Shire","startDate":"2020-10-27","conditions":"Healthy Volunteers","enrollment":51},{"nctId":"NCT06150833","phase":"PHASE3","title":"Efficacy and Safety and Pharmacokinetics of Boya IVIG","status":"UNKNOWN","sponsor":"Azidus Brasil","startDate":"2024-04-01","conditions":"Primary Immunodeficiency Disease","enrollment":50},{"nctId":"NCT03277313","phase":"PHASE3","title":"Efficacy, Safety, Tolerability, Immunogenicity and Pharmacokinetic Evaluation of HYQVIA in Pediatric PIDD Subjects","status":"COMPLETED","sponsor":"Baxalta now part of Shire","startDate":"2017-09-25","conditions":"Primary Immunodeficiency Diseases (PID)","enrollment":44},{"nctId":"NCT04566692","phase":"PHASE4","title":"A Study to Evaluate IGSC 20% Biweekly Dosing in Treatment-Experienced Participants and Loading/Maintenance Dosing in Treatment-Naïve Participants With Primary Immunodeficiency","status":"COMPLETED","sponsor":"Grifols Therapeutics LLC","startDate":"2020-11-24","conditions":"Primary Immunodeficiency","enrollment":33},{"nctId":"NCT06041451","phase":"PHASE4","title":"Early and Late Prognosis in Patients With Guillain-Barre Syndrome","status":"UNKNOWN","sponsor":"First Affiliated Hospital of Wenzhou Medical University","startDate":"2013-01-02","conditions":"Guillain-Barre Syndrome","enrollment":450},{"nctId":"NCT05986734","phase":"","title":"Evaluation of Subcutaneous Immunoglobulin Product Cutaquig in Terms of Safety and Efficacy in the Treatment of Patients With Primary Immunodeficiencies","status":"UNKNOWN","sponsor":"Federal Research Institute of Pediatric Hematology, Oncology and Immunology","startDate":"2022-09-01","conditions":"Primary Immunodeficiency Diseases (PID)","enrollment":100},{"nctId":"NCT05604859","phase":"PHASE4","title":"Evaluate the Efficacy and Safety of Various Treatment Schemes for Severe Fever With Thrombocytopenia Syndrome(SFTS)","status":"UNKNOWN","sponsor":"Qin Ning","startDate":"2022-08-19","conditions":"Severe Fever With Thrombocytopenia Syndrome","enrollment":350},{"nctId":"NCT03772717","phase":"NA","title":"Non-invasive Vagus Nerve Stimulation (nVNS) in Pediatric Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)","status":"TERMINATED","sponsor":"Emory University","startDate":"2022-02-22","conditions":"Chronic Inflammatory Demyelinating Polyneuropathy","enrollment":2},{"nctId":"NCT01231841","phase":"PHASE2","title":"Anti-thymocyte Globulin and Cyclosporine as First-Line Therapy in Treating Patients With Severe Aplastic Anemia","status":"COMPLETED","sponsor":"The Cleveland Clinic","startDate":"2005-03","conditions":"Aplastic Anemia","enrollment":20},{"nctId":"NCT05104762","phase":"PHASE2, PHASE3","title":"IVIG Versus Plasmapheresis in the Treatment of Guillian Barrie Syndrome Patients","status":"COMPLETED","sponsor":"Assiut University","startDate":"2021-09-01","conditions":"Guillain-Barre Syndrome","enrollment":81},{"nctId":"NCT01769027","phase":"PHASE2","title":"Antibiotic Treatment and Intravenous Immunoglobulin Trial for PANDAS","status":"WITHDRAWN","sponsor":"CNS Onlus","startDate":"2013-06","conditions":"Pandas","enrollment":""},{"nctId":"NCT01376778","phase":"PHASE3","title":"A Randomized Trial to Prevent Congenital Cytomegalovirus (CMV)","status":"COMPLETED","sponsor":"The George Washington University Biostatistics Center","startDate":"2012-04","conditions":"Congenital Cytomegalovirus Infection, Maternal Cytomegalovirus Infection","enrollment":399},{"nctId":"NCT00995059","phase":"PHASE1, PHASE2","title":"Bortezomib Before Donor Stem Cell Transplant in Treating Patients With Multiple Myeloma","status":"WITHDRAWN","sponsor":"Mayo Clinic","startDate":"","conditions":"Multiple Myeloma, Refractory Multiple Myeloma","enrollment":""},{"nctId":"NCT05494619","phase":"PHASE3","title":"A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Crovalimab in Participants With Guillain-Barré Syndrome (GBS)","status":"WITHDRAWN","sponsor":"Hoffmann-La Roche","startDate":"2022-11-30","conditions":"Guillain-Barré Syndrome","enrollment":""},{"nctId":"NCT04847141","phase":"PHASE3","title":"A Study to Evaluate the Safety and Efficacy of C19-IG 20% in SARS-CoV-2 Infected Asymptomatic Ambulatory Outpatients","status":"TERMINATED","sponsor":"Grifols Therapeutics LLC","startDate":"2021-04-28","conditions":"COVID-19, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection","enrollment":465},{"nctId":"NCT05634824","phase":"PHASE2","title":"IVIg Plus Low Dose rhTPO for ITP in Pregnancy","status":"UNKNOWN","sponsor":"Peking University People's Hospital","startDate":"2023-01-01","conditions":"Immune Thrombocytopenia, Pregnancy Related","enrollment":50},{"nctId":"NCT05134792","phase":"PHASE2, PHASE3","title":"Effect of Pre-emptive Intravenous Immunoglobulin (IVIG) on the Incidence of Septic Episodes in Pediatric Burn Patients","status":"COMPLETED","sponsor":"Cairo University","startDate":"2021-10-10","conditions":"Burn Shock","enrollment":30},{"nctId":"NCT01300728","phase":"PHASE2","title":"Study of Intravenous Immunoglobulin in Amnestic Mild Cognitive Impairment","status":"COMPLETED","sponsor":"Sutter Health","startDate":"2011-01-01","conditions":"Mild Cognitive Impairment","enrollment":52},{"nctId":"NCT04834908","phase":"PHASE1, PHASE2","title":"Evaluation of Equine Antibody Treatment in Patients With COVID 19 Infection","status":"TERMINATED","sponsor":"Bharat Serums and Vaccines Limited","startDate":"2021-07-27","conditions":"SARS-CoV-2 Infection","enrollment":7},{"nctId":"NCT04480424","phase":"PHASE2","title":"Study to Evaluate the Safety and Efficacy of High Dose Intravenous Immune Globulin (IVIG) Plus Standard Medical Treatment (SMT) Versus SMT Alone in Participants in Intensive Care Unit (ICU) With Coronavirus Disease (COVID-19)","status":"COMPLETED","sponsor":"Grifols Therapeutics LLC","startDate":"2020-09-17","conditions":"COVID-19","enrollment":100},{"nctId":"NCT05070455","phase":"PHASE4","title":"An Open Label, Multicenter Study to Evaluate the Pharmacokinetics, Efficacy and Safety of ASCENIV™ (IGIV) in Pediatric Subjects With Primary Immunodeficiency Diseases (PIDD)","status":"UNKNOWN","sponsor":"ADMA Biologics, Inc.","startDate":"2022-09-01","conditions":"Primary Immune Deficiency","enrollment":12},{"nctId":"NCT05367986","phase":"NA","title":"Electro-acupuncture at Zusanli, Qihai, and Guanyuan Acupoints Regulate Immune Function in Patients With Sepsis","status":"COMPLETED","sponsor":"Guangdong Provincial Hospital of Traditional Chinese Medicine","startDate":"2019-07-01","conditions":"Sepsis, Immune Dysfunction","enrollment":78},{"nctId":"NCT02240407","phase":"PHASE1","title":"Re-administration of Intramuscular AAV9 in Patients With Late-Onset Pompe Disease","status":"COMPLETED","sponsor":"University of Florida","startDate":"2017-10-17","conditions":"Pompe Disease","enrollment":2},{"nctId":"NCT02184741","phase":"PHASE3","title":"A Study of the Efficacy and Safety of GB-0998 in Patients With Unexplained Recurrent Miscarriage","status":"COMPLETED","sponsor":"Japan Blood Products Organization","startDate":"2014-06-03","conditions":"Recurrent Miscarriage","enrollment":99},{"nctId":"NCT02040090","phase":"PHASE2, PHASE3","title":"Phase II/III Study of the Safety and Effectiveness of HRIG With Active Rabies Vaccine in Healthy Subjects","status":"COMPLETED","sponsor":"Kamada, Ltd.","startDate":"2013-04","conditions":"Rabies","enrollment":118},{"nctId":"NCT04035135","phase":"PHASE1","title":"A Clinical Study of ANX005 and IVIG in Subjects With Guillain Barré Syndrome (GBS)","status":"COMPLETED","sponsor":"Annexon, Inc.","startDate":"2020-01-29","conditions":"Guillain-Barré Syndrome","enrollment":14},{"nctId":"NCT00473824","phase":"PHASE2","title":"Randomized Phase II Study of Hepatitis C Immune Globulin Intravenous (Human), Civacir(TM), in Liver Transplantation","status":"TERMINATED","sponsor":"ADMA Biologics, Inc.","startDate":"2007-05","conditions":"Sequelae of Viral Hepatitis, Transplantation Infection, Evidence of Liver Transplantation","enrollment":7},{"nctId":"NCT02303093","phase":"","title":"Non-Interventional Study on the Tolerability and Efficacy of IVIG","status":"COMPLETED","sponsor":"Octapharma","startDate":"2011-08-01","conditions":"Primary and Secondary Immunodeficiency and Other Conditions Requiring Regular Administration of Octagam 5% or 10% IVIG","enrollment":344},{"nctId":"NCT00666263","phase":"PHASE3","title":"Study of the Effectiveness of Intravenous Immune Globulin (10%) for the Treatment of Multifocal Motor Neuropathy","status":"COMPLETED","sponsor":"Baxalta now part of Shire","startDate":"2008-08-22","conditions":"Multifocal Motor Neuropathy","enrollment":50},{"nctId":"NCT02129582","phase":"PHASE1","title":"Targeted Marrow Irradiation, Fludarabine Phosphate, and Busulfan Before Donor Progenitor Cell Transplant in Treating Patients With Hematologic Malignancies","status":"COMPLETED","sponsor":"Case Comprehensive Cancer Center","startDate":"2014-11-05","conditions":"Acute Myeloid Leukemia, Hematologic Malignancies, Acute Lymphocytic Leukemia","enrollment":14},{"nctId":"NCT02013037","phase":"PHASE3","title":"The De-novo Use of Eculizumab in Presensitized Patients Receiving Cardiac Transplantation","status":"COMPLETED","sponsor":"Cedars-Sinai Medical Center","startDate":"2012-11","conditions":"Antibody-mediated Rejection, Hyperacute Rejection of Cardiac Transplant, Left Ventricular Dysfunction","enrollment":36},{"nctId":"NCT04535518","phase":"PHASE3","title":"Efficacy of Immunoglobulin Plus Infliximab for the Early Regression of Coronary Artery Lesion in Kawasaki Disease","status":"WITHDRAWN","sponsor":"Children's Hospital of Fudan University","startDate":"2020-10","conditions":"Kawasaki Disease","enrollment":""},{"nctId":"NCT04432324","phase":"PHASE2","title":"Study to Evaluate the Safety and Efficacy of High Dose IVIG in Hospitalized Participants With Coronavirus Disease (COVID-19)","status":"COMPLETED","sponsor":"Instituto Grifols, S.A.","startDate":"2020-06-02","conditions":"COVID-19","enrollment":100},{"nctId":"NCT04550611","phase":"NA","title":"Mini-pool Intravenous Immunoglobulin (MP-IVIG) in Guillain-Barré Syndrome","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2021-11","conditions":"Guillain-Barre Syndrome","enrollment":50},{"nctId":"NCT03380936","phase":"EARLY_PHASE1","title":"Pilot Study of Treatment for Subclinical AMR (Antibody-mediated Rejection) in Kidney Transplant Recipients","status":"TERMINATED","sponsor":"University of Colorado, Denver","startDate":"2018-01-17","conditions":"Kidney Transplant Rejection","enrollment":4},{"nctId":"NCT02540720","phase":"PHASE2","title":"The Research of Standard Diagnosis and Treatment for Severe HSP in Children","status":"UNKNOWN","sponsor":"Nanjing Children's Hospital","startDate":"2015-08","conditions":"Henoch-Schoenlein Purpura","enrollment":30},{"nctId":"NCT04261426","phase":"PHASE2, PHASE3","title":"The Efficacy of Intravenous Immunoglobulin Therapy for Severe 2019-nCoV Infected Pneumonia","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2020-02-10","conditions":"2019-nCoV","enrollment":80},{"nctId":"NCT02697292","phase":"PHASE3","title":"IVIG in Patients With VGKC Ab Associated Autoimmune Epilepsy","status":"TERMINATED","sponsor":"Mayo Clinic","startDate":"2016-02","conditions":"Autoimmune Epilepsy","enrollment":17},{"nctId":"NCT02690038","phase":"PHASE2","title":"Ig PRx in AECOPD: Pilot Study","status":"COMPLETED","sponsor":"Ottawa Hospital Research Institute","startDate":"2016-09","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":48},{"nctId":"NCT03018652","phase":"PHASE2","title":"Feasibility and Safety of Immunoglobulin (Ig) Treatment in COPD Outpatients With Frequent Exacerbations: Pilot Study 1","status":"COMPLETED","sponsor":"Ottawa Hospital Research Institute","startDate":"2018-03-11","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":22},{"nctId":"NCT03348618","phase":"PHASE4","title":"A Study to Evaluate the Benefit of Octagam 5%® in Subjects With Pediatric Acute-onset Neuropsychiatric Syndrome (PANS)","status":"UNKNOWN","sponsor":"IMMUNOe Research Centers","startDate":"2017-11-24","conditions":"Pediatric Acute-Onset Neuropsychiatric Syndrome, Pediatric Autoimmune Neuropsychiatric Disorders Associated With Streptococcal Infections","enrollment":21},{"nctId":"NCT00856388","phase":"NA","title":"Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Bone Marrow Failure Disorders","status":"COMPLETED","sponsor":"Roswell Park Cancer Institute","startDate":"2009-01-14","conditions":"Accelerated Phase Chronic Myelogenous Leukemia, Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Adult Acute Lymphoblastic Leukemia in Remission","enrollment":62},{"nctId":"NCT01854827","phase":"PHASE1, PHASE2","title":"Safety Study of Intravenous Immunoglobulin (IVIG) Post-Portoenterostomy in Infants With Biliary Atresia","status":"COMPLETED","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2013-10","conditions":"Biliary Atresia","enrollment":30},{"nctId":"NCT02176239","phase":"","title":"Monitoring of 5% Treatment Naïve Intravenous Immunoglobulin (IVIg) Primary Immunodeficiency Disease (PIDD) Patients Using the CareExchange® System: A Pilot Study Using 5% Gammaplex® IVIg in the Home Setting","status":"COMPLETED","sponsor":"BriovaRx Infusion Services","startDate":"2014-06","conditions":"Primary Immunodeficiency Disease (PIDD)","enrollment":20},{"nctId":"NCT01561053","phase":"PHASE2, PHASE3","title":"A Study to Evaluate Albumin and Immunoglobulin in Alzheimer's Disease","status":"COMPLETED","sponsor":"Instituto Grifols, S.A.","startDate":"2012-04-19","conditions":"Alzheimer's Disease","enrollment":347},{"nctId":"NCT01859754","phase":"","title":"Octagam 5% Versus Comparator Post Marketing Trial","status":"COMPLETED","sponsor":"Octapharma","startDate":"2013-05-21","conditions":"Primary Immune Deficiency Disorder","enrollment":623},{"nctId":"NCT01203345","phase":"PHASE2, PHASE3","title":"Intravenous Immune Globulin (IVIG) to Prevent Neonatal Infection","status":"COMPLETED","sponsor":"NICHD Neonatal Research Network","startDate":"1988-01","conditions":"Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age","enrollment":2416}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Gammaplex (5%)","genericName":"Gammaplex (5%)","companyName":"Bio Products Laboratory","companyId":"bio-products-laboratory","modality":"Biologic","firstApprovalDate":"","aiSummary":"Gammaplex is an intravenous immunoglobulin (IVIG) preparation that provides passive immunity by delivering pooled human antibodies to boost immune function. Used for Primary immunodeficiency disorders, Secondary immunodeficiency (e.g., chronic lymphocytic leukemia, HIV), Idiopathic thrombocytopenic purpura (ITP).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}